DIP Database of Interacting Proteins 611 Young Drive East; Los Angeles CA 90095; USA http://dip.doe-mbi.ucla.edu/ dip@mbi.ucla.edu SARS-CoV-2 M^pro inhibitors with antiviral activity in a transgenic mouse model. SARS-CoV-2 M^pro inhibitors with antiviral activity in a transgenic mouse model. Science (New York, N.Y.) 2021 imex curation Qiao J., Li YS., Zeng R., Liu FL., Luo RH., Huang C., Wang YF., Zhang J., Quan B., Shen C., Mao X., Liu X., Sun W., Yang W., Ni X., Wang K., Xu L., Duan ZL., Zou QC., Zhang HL., Qu W., Long YH., Li MH., Yang RC., Liu X., You J., Zhou Y., Yao R., Li WP., Liu JM., Chen P., Liu Y., Lin GF., Yang X., Zou J., Li L., Hu Y., Lu GW., Li WM., Wei YQ., Zheng YT., Lei J., Yang S. yangsy@scu.edu.cn (S.Y.); leijian@scu.edu.cn (J.L.); zhengyt@mail.kiz.ac.cn (Y.-T.Z.) Only protein-protein interactions imex curation ecoli Escherichia coli (strain K12) x-ray diffraction x-ray crystallography X-ray X-ray x-ray diffraction experimental particp experimental participant identification experimental particp Qiao J., Li YS., Zeng R., Liu FL., Luo RH., Huang C., Wang YF., Zhang J., Quan B., Shen C., Mao X., Liu X., Sun W., Yang W., Ni X., Wang K., Xu L., Duan ZL., Zou QC., Zhang HL., Qu W., Long YH., Li MH., Yang RC., Liu X., You J., Zhou Y., Yao R., Li WP., Liu JM., Chen P., Liu Y., Lin GF., Yang X., Zou J., Li L., Hu Y., Lu GW., Li WM., Wei YQ., Zheng YT., Lei J., Yang S. yangsy@scu.edu.cn (S.Y.); leijian@scu.edu.cn (J.L.); zhengyt@mail.kiz.ac.cn (Y.-T.Z.) Accepted 2021-JUN-04 AT 14:35 BST AT 14:35 BST by ORCHARD Science (New York, N.Y.) 2021 Only protein-protein interactions imex curation imex curation boceprevir boceprevir boceprevir SCH 503034 Victrelis (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide small molecule small molecule chemical synthesis Chemical synthesis (Chemical synthesis) p0dtd1-pro_0000449623 3C-like proteinase nsp5 rep ORF1ab polyprotein 1a-1b protein protein SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 2019-nCoV SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIRKSNHNFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGNFYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ 3264 3569 telaprevir telaprevir (1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamide Incivek VX 950 VX-950 (1S,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]octahydrocyclopenta[c]pyrrole-1-carboxamide small molecule small molecule chemical synthesis Chemical synthesis (Chemical synthesis) rep-telaprevir-1 1 4 unspecified role unspecified role unspecified role unspecified role 3 predetermined predetermined participant predetermined structure determination identification by structure determination identification by structure determination structure determination experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified ecoli Escherichia coli (strain K12) direct interaction direct interaction Fig. 2, Table S2 boceprevir-rep-1 1 2 unspecified role unspecified role unspecified role unspecified role 3 predetermined predetermined participant predetermined structure determination identification by structure determination identification by structure determination structure determination experimental particp experimental participant identification experimental particp unspecified role unspecified role neutral component neutral component purified purified ecoli Escherichia coli (strain K12) direct interaction direct interaction Fig. 2, Table S2